Wyeth and Progenics Begin Phase II Trial of Oral Methylnaltrexone

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 9
Volume 15
Issue 9

Wyeth Pharmaceuticals and Progenics Pharmaceuticals, Inc. (Tarrytown, New York) have begun a phase II clinical trial to evaluate once-daily dosing of oral methylnaltrexone, a peripheral mu opioid-receptor antagonist designed to reverse the effect of opioids on opioid receptors outside the central nervous system, thus reducing opioid-induced constipation. The trial is designed to identify the dose(s) of methylnaltrexone to be taken forward into the phase III studies.

MADISON, New Jersey—Wyeth Pharmaceuticals and Progenics Pharmaceuticals, Inc. (Tarrytown, New York) have begun a phase II clinical trial to evaluate once-daily dosing of oral methylnaltrexone, a peripheral mu opioid-receptor antagonist designed to reverse the effect of opioids on opioid receptors outside the central nervous system, thus reducing opioid-induced constipation. The trial is designed to identify the dose(s) of methylnaltrexone to be taken forward into the phase III studies.

Related Videos
Acupuncture
Related Content